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Abstract 
Background: Nanotechnology is a science that involves imaging, measurement, modeling and a manipulation of mat‑
ter at the nanometric scale. One application of this technology is drug delivery systems based on nanoparticles obtained 
from natural or synthetic sources. An example of these systems is synthetized from poly(3‑hydroxybutyrate‑co‑3‑hy‑
droxyvalerate), which is a biodegradable, biocompatible and a low production cost polymer. The aim of this work was to 
investigate the uptake mechanism of PHBV nanoparticles in two different epithelial cell lines (HeLa and SKOV‑3).
Results: As a first step, we characterized size, shape and surface charge of nanoparticles using dynamic light scat‑
tering and transmission electron microscopy. Intracellular incorporation was evaluated through flow cytometry and 
fluorescence microscopy using intracellular markers. We concluded that cellular uptake mechanism is carried out 
in a time, concentration and energy dependent way. Our results showed that nanoparticle uptake displays a cell‑
specific pattern, since we have observed different colocalization in two different cell lines. In HeLa (Cervical cancer 
cells) this process may occur via classical endocytosis pathway and some internalization via caveolin‑dependent was 
also observed, whereas in SKOV‑3 (Ovarian cancer cells) these patterns were not observed. Rearrangement of actin 
filaments showed differential nanoparticle internalization patterns for HeLa and SKOV‑3. Additionally, final fate of 
nanoparticles was also determined, showing that in both cell lines, nanoparticles ended up in lysosomes but at differ‑
ent times, where they are finally degraded, thereby releasing their contents.
Conclusions: Our results, provide novel insight about PHBV nanoparticles internalization suggesting that for develop 
a proper drug delivery system is critical understand the uptake mechanism.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Nanotechnology is the science of engineering materi-
als and systems on a molecular scale. Its application to 
medicine, “nanomedicine”, has enabled the development 
of nano-sized drug-delivery vehicles. These nanocarriers 
are generally <200 nm in size and have the ability to carry 
and deliver therapeutics to discrete sites into the cells [1].
Due to their small size, increased stability and sus-
tained drug release properties, biodegradable polymeric 
nanocarriers display several advantages, being more 
effective for cancer treatment than other nanoparticles 
(e.g. metallic ones) [2]. Nanoparticles are being devel-
oped for in  vivo tumor imaging, targeted drug delivery 
and biomolecular profiling of cancer biomarkers. Biode-
gradable polymeric nanoparticles (NPs) have been shown 
promissory as controlled drug delivery systems, showing 
high therapeutic potential [3]. Currently, delivery tech-
nologies using cell-targeting [4, 5] or specific targeting 
of organelles inside a cell [6] are becoming increasingly 
important as an area of scientific investigation. In cancer, 
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polymeric NPs can be used to deliver chemotherapeutics 
towards tumor cells, with high efficiency and reduced 
cytotoxicity on healthy tissues [6–8]. The activity of the 
drug carried by the NPs depends on how and where the 
NPs are disassembled. The mechanism of NPs endocyto-
sis and trafficking is still a subject of controversy [9–11].
Among polymeric NPs, (3-hydroxybutyric acid-co-3 
hydroxyvaleric acid) (PHBV) constitutes a promissory 
alternative, more accessible and cheaper than similar pol-
ymers such as poly (lactic-co-glycolic acid) (PLGA); the 
last one has been widely used in drug delivery in different 
cancer types and have an FDA approval [12, 13]. PHBV 
is a biodegradable and biocompatible polyester, composed 
of two monomers: hydroxybutyrate and hydroxyvalerate 
and, since it is produced by bacteria or eukaryotic cells, 
it can be synthesized in large scales [14]. However, at pre-
sent, little is known about its uptake and distribution into 
mammalian cells [14].
In the case of hydroxybutyrate-composed homopoly-
mers (PHB), it has been described that is primarily found 
complexed with other molecules, and can be found in 
several subcellular organelles of eukaryotic organisms 
[15] or associated with proteins [16]. A previous study 
has suggested that PHB is associated in granules that 
accumulate in the cytoplasm, similar to the behavior in 
bacteria, which might constitute an ‘energy reservoir’. 
In the same study, the colocalization of PHV granules 
with organelles was inspected in U87 cells, showing no 
remarkable colocalization with lysosomes, mitochondria, 
or endoplasmic reticulum [17].
PHBV copolymer reduces the chain packing and 
decreases crystalline melting point, due to the ethyl chain 
of the valerate, which increases flexibility, impact strength, 
and ductility in comparison to hydroxybutyrate homopol-
ymer [18]. Furthermore, previous studies have revealed the 
usefulness of PHBV nanoparticles in the encapsulation of 
paclitaxel drugs, protecting this anticancer agent against 
premature degradation, by allowing 48  h of toxicity pro-
tection. Other applications of PHBV in medicine include 
a formulation loaded with antibiotics for veterinary uses, 
which allows protecting the drug for inactivation [19].
Previous work demonstrates that most NPs, includ-
ing those formed from biodegradable polymers such as 
PLGA, are taken up by an endocytic process, and their 
uptake is concentration- and time-dependent [12, 20, 
21]. PLGA NPs for delivery of therapeutics are of par-
ticular interest due to their biocompatibility, biodegrada-
bility and ability to maintain therapeutic drug levels for 
sustained periods of time [22]. However, further inves-
tigation is required to determine the mechanisms and 
therapeutic potential of intracellular targeting of nano-
delivery systems in vivo for the goal of an anticancer vac-
cine [14].
Other studies on PLGA uses for targeting have shown 
that the intracellular fate of nanoparticles may be altered 
by their surface decoration with a targeting molecule. 
In the case of PLGA, previous studies in smooth muscle 
cells have revealed that these NPs can undergo exocy-
tosis in about 65%; meaning that the NPs are effectively 
internalized, but they escape from the cells before releas-
ing their content [23]. The fraction of NPs that escapes 
from the endosomes to the cytosolic compartments was 
shown to be retained inside cells, delivering the encap-
sulated agent slowly [24]. The polymer matrix prevents 
the degradation of the drug and the duration and levels 
of drug released from the NPs can be easily modulated by 
altering the formulation. Meanwhile, in hepatoma cells, 
it has been described that PLGA NPs are taken up by the 
classical clathrin pathway and that they effectively escape 
from lysosomes and contribute to enhancing the effi-
ciency of intracellular delivery and tumor therapy [25].
In summary, discovering the intracellular fate of NPs 
and the investigation of their endocytic mechanism is 
particularly significant with the aim of using them as drug 
carriers, since in some cases, they may be taken back to 
the extracellular media (via recycling endosomes), or 
they may be degraded in lysosomes or be trapped in an 
organelle, without releasing its content at the desired site 
[12, 26, 27]. Furthermore, escaping from the endosomes 
to reach other organelles is another important issue to be 
addressed.
The present manuscript aims to provide insights about 
the possible routes of internalization and escaping from 
the endosomal sorting pathway of PHBV nanoparticles, 
in two different cell lines: in HeLa (cervix cancer) and 
SKOV-3 (ovarian cancer). HeLa cells was chosen because 
its endocytic machinery is very well characterized, and 
SKOV-3 cells because these cells are challenging due to 
their common chemoresistance [28] in order to inves-
tigate how a possible drug treatment (encapsulated in a 
nanoparticle) may stay inside the cell, where normally 
drugs are pumped out.
Several compartments, such as early endosomes (Trans-
ferrin Conjugate or EEA1 antibody), late endosomes 
(Lysotracker or Rab7 antibody) and lysosomes (Lysotracker 
or LAMP1 antibody), were chosen for this investigation, 
as they are involved in transport, destination, release, and 
degradation of soluble and membrane-bound macromol-
ecules [29]. Endosome and lysosome formation require 
microtubules to form a network in the cytoplasm, whereas 
actin generates forces to induce membrane invaginations 
[30, 31], thereby microtubules and actin cytoskeleton were 
also analyzed.
These methods may contribute to the development 
of PHBV NPs as drug carriers, enabling to enhance the 
delivery of chemotherapeutics inside the cells.
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Methods
Materials
Poly (3-hydroxybutyric acid-co-hydroxyvaleric acid) 
(PHBV) with 12 wt% PHV and polyvinyl alcohol (PVA) 
(average mol wt. 30,000–70,000) and glutathione were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Nile 
Red 552/636 was purchased from Invitrogen (Carlsbad, 
CA, USA). Dichloromethane (DCM), dimethyl sulfox-
ide (DMSO) and methanol were purchased from Merck 
(Darmstadt, Germany). The primary antibody Anti-EEA1 
(Early Endosome Antigen 1) was purchased in Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), the anti-Cave-
olin-1 and anti-LAMP1 (Lysosomal-associated mem-
brane protein 1) were obtained from Abcam (Cambridge, 
USA). The secondary antibodies Alexa Fluor 488 Donkey 
Anti-Mouse IgG (H + L), and Alexa Fluor 488 Goat Anti-
Rabbit IgG (H + L) were purchased in Molecular Probes 
by Life Technologies (Carlsbad, CA, USA). Additionally, 
membrane glycoproteins marker Wheat Germ Aggluti-
nin, Alexa Fluor 555 Conjugate (WGA), actin (F-actin) 
Alexa Fluor 488 phalloidin, LysoTracker® Red DND-99 
and Hoechst 33342 were obtained from Molecular Probes 
by Life Technologies (Carlsbad, CA, USA). Fluoromount 
G was purchased in Electron Microscopy Sciences (Hat-
field, PA, USA), and EZ-Link® NHS-SS-Biotin was 
obtained from Pierce Biotechnology (Rockford, IL, USA).
Preparation of PHBV nanoparticles
PHBV nanoparticles (NPs) were formulated via a modifi-
cation of the double emulsion (w1/o1/w2) solvent-evapo-
ration method [19]. Briefly, 400 µL of distilled water were 
added to 1 mL of a solution of 3 mg/mL of PHBV (Sigma-
Aldrich, Co., St. Louis, MO, USA) in dichloromethane 
(Merck KGaA, Darmstadt, Germany). The first emulsion 
(w1/o1) was prepared by sonication in an ultrasonic pro-
cessor equipped with a microtip probe for 40 s at 100% in 
an ice bath. The water-in-oil emulsion was further emul-
sified by sonication under the same conditions in 4  mL 
of an aqueous solution of 5 mg/mL PVA (w2). This w1/
o1/w2 emulsion was immediately poured into a beaker 
containing 20  mL of a 0.5  mg/mL PVA solution. The 
mixture was stirred with an overhead propeller for 12 h 
under a flow hood, and the solvent was allowed to evapo-
rate. The remaining organic solvent and free molecules 
were removed by passing the particle solution 3 times 
through an Amicon Ultra-4 centrifugal filter. Finally, NPs 
were concentrated by centrifugation and resuspended 
in 500 μL of phosphate buffered saline (PBS, pH 7.4) for 
further use. A modification of the technique described 
was used for the synthesis of functionalized nanopar-
ticles with a marker. The same procedure was followed, 
except the aqueous phase (W1) was replaced by 100 μL 
of a solution of fluorescein isothiocyanate (FITC) 1 mg/
mL; 100 μL of a solution of Nile Red (RN) 1 mg/mL; or 
5 μL of the LysoTracker® Red DND-99 fluorescent probe.
PHBV nanoparticles characterization by dynamic light 
scattering (DLS)
Each preparation was suspended in 1 mL of PBS pH 7.4 
and nanoparticles diameter (nm), polydispersity coef-
ficient (PdI) and zeta potential (mV) were determined 
by light scattering technique using a Zetasizer Nano-ZS 
(Malvern Instruments Ltd., UK).
Transmission electron microscopy (TEM)
NPs structure was also characterized using transmission 
electron microscopy. One drop of the NP sample was 
placed onto an ultra-thin Lacey carbon-coated 400-mesh 
copper grid and allowed to dry at room temperature for 
10 min prior to image acquisition, ensuring no more than 
1  min of electron beam exposure to the sample. TEM 
images were acquired using an LVEM5 electron micro-
scope (Delong Instrument, Montreal, Quebec, Canada) 
at a nominal operating voltage of 5  kV. The small vol-
ume of the vacuum chamber in the LVEM5 microscope 
facilitates rapid sample visualization within 3 min before 
observation. The low voltage used delivers high contrast 
in soft materials (up to 20-fold) compared with high-volt-
age electron microscopes, which use accelerating volt-
ages of approximately 100  kV; this procedure facilitates 
the emission of staining procedures and allows the direct 
visualization of biological samples. Digital images were 
captured using a Retiga 4000R camera (QImaging, Inc., 
USA) at its maximal resolution.
Cell culture
The Human cervical adenocarcinoma HeLa and the 
human ovarian adenocarcinoma SKOV-3 were obtained 
from the American Type Culture Collection (ATCC® 
CCL-2™, and ATCC® HTB-77™ respectively). The cells 
were maintained in Dulbecco’s High Glucose Modified 
Eagle’s Medium (DMEM) supplemented with 10% v/v 
fetal bovine serum, 1  mM sodium pyruvate and 1% v/v 
penicillin–streptomycin (Hyclone™ Laboratories, Inc., 
South Logan, UT, USA), and incubated at 37  °C and 5% 
CO2. Peripheral blood mononuclear cell (PBMC) were 
obtained using a Ficoll® density gradient, and cultured 
in Roswell Park Memorial Institute Medium (RPMI) 
1640, which was supplemented with 10% v/v fetal bovine 
serum and 1% penicillin–streptomycin (Hyclone™ Labo-
ratories, Inc., South Logan, UT, USA) and incubated at 
37 °C and 5% CO2.
Flow cytometry
HeLa and SKOV-3 cells (2 × 105 cells/well) were seeded 
separately in 6-well plates and incubated for 48  h. 
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Subsequently, to evaluate time-dependent intracellular 
incorporation, a solution of PHBV-RN 100  μg/mL was 
added in culture medium for 5, 15, 30  min, 1 and 2  h. 
To assess the dependence of the concentration, differ-
ent concentrations (1, 10, 100, 500 and 1000  μg/mL) of 
a PHBV-RN solution were added and incubated for 2 h. 
Additionally, to evaluate the dependence of the energy, 
cells were incubated at 4 °C or with a sodium azide (AS) 
solution 1  mg/mL (Sigma-Aldrich, Co., St. Louis, MO, 
USA) for 1  h respectively. Then, a PHBV-RN solution 
(100  μg/mL) was added and incubated for 2 additional 
hours. After the incubation time, cells were washed 3 
times with cold PBS, detached from the culture plate with 
PBS-EDTA 0.2% (w/v), incubated for 15  min at 37  °C, 
then washed twice with buffer FACS (PBS-2% FBS) and 
resuspended in 500  μL of PBS. Finally, the fluorescence 
intensity of cells containing fluorescent nanoparticles was 
analyzed using a flow cytometer BD Accuri C6™ and v1.0 
software (BD™, Franklin Lakes, NJ, USA).
Immunofluorescence
Cell lines were plated at a confluence of 70–80% in 
24-well plates with coverslips. A PHBV-FITC or PHBV-
RN nanoparticles solution was added and incubated for 
different times. Then, cells were washed 2 times with 
PBS, fixed with paraformaldehyde (PFA) 4% for 10 min, 
washed 3 times with PBS and then permeabilized with 
Triton X-100 0.1% by 10  min. Then, cells were washed 
2 times with PBS and then cells were incubated with a 
primary antibody (1:100) for 1 h at RT. Then, cells were 
washed 5 times again with PBS and incubated with a 
secondary antibody (1:500) for 1  h at RT. Nucleic acid 
marker Hoechst 33342 (1:1000) was added for 15  min 
and finally cells were washed 5 times with PBS. Cover-
slips were mounted on a slide using Fluoromount G 
mounting medium for subsequent microscopic obser-
vation. Slides were observed using a BX61 fluorescence 
microscope (Olympus Corp., Tokyo, Japan), coupled to 
an ORCA-R2 (Hamamatsu Photonics KK, Japan) cam-
era. Images were analyzed by Dimension cellSens v1.7.1 
software (Olympus Corp., Tokyo, Japan). Colocaliza-
tion percentages were based on the merge between the 
two channels red and green. For this, we use Image J 
v1.48 software using the plugin Colocalization Threshold 
which creates a threshold for pixels of the red and green 
channels. Pixels below this threshold are ignored for the 
quantification of colocalization.
Reducible biotin assay
To analyze the involvement of proteins involved in 
endocytosis of nanoparticles, we performed an experi-
ment using reducible biotin. When biotinilated proteins 
are internalized, they become resistant to extracellular 
reducing solution, allowing distinction between endocy-
tosed and not endocytosed proteins. Experiment were 
performed at 4  °C. Cells were grown to 70–80% conflu-
ence in 6-well plates and washed 3 times with cold PBS. 
Biotin (0.5 mg/mL) were incubated for 20 min two times 
with gentle shaking. Free biotin was blocked adding a 
solution of 50 mM NH4Cl for 10 min, and then cells were 
washed 3 times with PBS. For the reduction, a solution 
containing glutathione 50  mM, 90  mM NaCl, 10% FBS, 
1 mM MgCl2, 0.1 mM CaCl2 and 60 mM NaOH to a final 
pH of 7.2–7.4 was used. Cells were incubated with the 
solution two times for 30 min at 4  °C with gentle shak-
ing. Then cells were incubated with lysis buffer (contain-
ing antiproteases) with gentle agitation for 30  min at 
4 °C. The obtained extract was centrifuged for 30 min at 
14,000 rpm at 4 °C and the pellet was discarded. Proteins 
were quantified using Qubit® 2.0 Fluorometer. 30  µg of 
protein were denatured in protein loading buffer and 
incubated at 95 °C for 5 min. Samples were loaded onto a 
polyacrylamide gel 12% acrylamide-bis.
Western blot
Electrophoresis was performed at 120  V constant cur-
rent in running buffer in a vertical electrophoresis cham-
ber model Mini PAGE System. After electrophoresis, 
proteins were transferred to a preactivated PVDF mem-
brane in 100% methanol. The transfer was carried out in 
a transfer model system Trans-Blot® Turbo™. The PVDF 
membrane was blocked with gentle agitation for 2  h at 
room temperature in PBS-Tween 20 0.5, 10% glycerol, 
glucose 1 M BSA 3% skim milk and 1%. After blocking, 
the membrane was washed 4 times for 15 min with PBS-
0.05% Tween 20 and subsequently incubated for 2  h at 
room temperature with streptavidin horseradish peroxi-
dase conjugated (1:1000) in PBS with 0.5% Tween 20, 10% 
glycerol, 1 M glucose, 0.3% BSA. Finally, the membrane is 
washed 4 times for 15 min with PBS-0.05% Tween 20. For 
the development of the membrane substrate SuperSignal 
West Femto Chemiluminescent substrate (Thermo Fisher 
Scientific Inc., Rockford, IL, USA) was used according 
to manufacturer’s instructions. Development was car-
ried out in the PHOTO/Analyst® Luminary/FX® Systems 
equipment and using the FOTO/Analyst® PC Image v5.0 
(Fotodyne Inc., Hartland, WI, USA) software.
MTT assay
Toxicity of the nanoparticles was determined using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) cell viability assay. MTT is a yellow com-
pound that when reduced by functioning mitochondria, 
produces purple formazan crystals that can be measured 
spectrophotometrically. For this purpose, HeLa cells 
were incubated with different concentrations of PHBV 
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solution for 24 h at 37 °C and 5% CO2. After incubation 
time, MTT (Sigma-Aldrich) was dissolved in phosphate 
buffered saline (PBS) to a concentration of 5 mg/mL and 
further diluted in culture medium (1:11). Cells were incu-
bated with this MTT-solution for 3 h under normal cul-
ture conditions. Afterwards 155 μL of the solution were 
rejected and 90 μL of DMSO were added. To completely 
dissolve the formazan salts plates were incubated for 
10 min on a shaker and afterwards quantified by measur-
ing the absorbance at 535  nm with a ELISA microplate 
reader. Cell viability was calculated as percentage of sur-
viving cells compared to untreated control cells.
Results and discussion
Characterization of PHBV nanoparticles
Double emulsion solvent evaporation method was used 
to formulate four preparations of PHBV nanoparticles: 
PHBV-empty (control), FITC-loaded PHBV NPs (PHBV-
FITC), Nile Red-loaded PHBV NPs (PHBV-RN), and 
Lysotracker-loaded PHBV NPs (PHBV-Lysotracker®). This 
w/o/w method was selected due of the broad experience of 
our group in the formulation of NPs, and the incorpora-
tion of dyes in the aqueous or organic phase was according 
to its solubility. The characterization of size and morphol-
ogy of NPs was performed using dynamic light scattering 
(DLS) and by transmission electron microscopy (TEM). 
Table 1 describes the diameter (nm), polydispersity index 
(PdI), and the Zeta Potential (mV) obtained of NPs, and 
Additional file 1: Figure S1 exhibits a graphical representa-
tion of the data analyzed statistically. The size presented in 
all formulations of NPs was homogenous with a diameter 
of  ~200  nm, stable in time (Additional file  2: Figure S2), 
and similar to the size of paclitaxel-loaded PHBV nanopar-
ticles synthesized previously by our group [32].
Studies have revealed a direct relationship between 
the size of the NPs and the endocytic pathway. Particles 
with a size less than 200 nm were internalized into non-
phagocytic, murine melanome cells B16-F10 via clathrin-
mediated endocytosis. The size of clathrin-coated pits 
varies between different cell types within the same spe-
cies [33]. The size of clathrin-coated vesicles depends 
on the size of its cargo, having an upper limit of 200 nm 
external diameter in the case of virus uptake [34].
In a similar way, 50 and 120  nm folate-decorated 
poly(ethylene glycol)-polycaprolactone nanoparticles 
were found to be internalized via both clathrin- and cav-
eolae-mediated endocytosis in ARPE-19 cells. However, 
250  nm nanoparticles, were only internalized via cave-
olae-mediated pathway [35], despite some articles have 
described an upper limit size of  ~150  nm for passage 
through caveolae vesicles [36].
In a more recent article, glycopeptide engineered 
PLGA nanoparticles, closely related to the PHBV nano-
particles studied here, were investigated to determine 
their endocytic mechanism. As demonstrated by confo-
cal microscopy analysis, these nanoparticles, 170  nm in 
diameter, strongly colocalized with clathrin related-but 
not with caveolin related-routes [37].
Figure 1 shows a representative micrograph of control 
preparation, which was obtained through transmission 
electron microscopy (TEM). In this figure, the spherical 
morphology and uniform nanoparticle size is evidenced. 
It has been reported that nanoparticle morphology may 
influence its internalization into the cells. In previous 
reports, spherical-shaped gold NPs displayed higher 
and faster rate of endocytosis than disk or rod-shaped 
nanoparticles [38]. In contrast, other researchers have 
suggested a preferential internalization of polyethylene 
glycol nanoparticles having a rod or cylindrical shape 
[39]. All these records indicate that spherical morphology 
of PHBV nanoparticles may not be decisive in entering 
the cells, but the setting of other features—such as the 
chemical nature, size, and charge—are also implied in 
how they are taken up.
Surface charge of nanoparticles is another important 
parameter to characterize because the surface of the 
nanoparticle interacts directly with the biological envi-
ronment. Due to the chemical nature conferred by the 
phospholipids, the plasma membrane has a negative 
charge. For this reason, positively-charged drug delivery 
systems exhibit better adhesion and a higher internaliza-
tion rate. An example of this phenomenon has been dem-
onstrated by Harush-Frenkel et al., who revealed in HeLa 
cells, that polymeric nanoparticles of PLA-PEG coated 
with cationic lipid stearylamine (~ +35  mV) evidence 
greater incorporation than the same NPs but negatively 
charged (~ −35  mV) [40]. However, in the case of pos-
sible use in vivo of these nanoplatforms, the interaction 
with plasma proteins is reduced if the NPs are negatively 
charged, decreasing the probabilities of activation of 
immune response by monocytes and macrophages in the 
bloodstream [41].
Uptake measurement of PHBV nanoparticles
To characterize how PHBV nanoparticles are taken up by 
the cells, we quantified their incorporation through flow 
Table 1 Nanoparticle physicochemical characterization: 
size, zeta potential and polydispersity index (PdI) (n = 5)
Size (nm) PdI Zeta potential (mV)
PHBV 200.2 ± 3.66 0.133 ± 0.020 −11.7 ± 1.97
PHBV‑FITC 201.7 ± 10.4 0.100 ± 0.023 −9.60 ± 1.25
PHBV‑RN 206.0 ± 3.37 0.204 ± 0.043 −7.96 ± 0.41
PHBV‑Lysotracker® 201.5 ± 7.19 0.206 ± 0.021 −5.16 ± 1.99
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cytometry. This measurement was performed under dif-
ferent conditions, including the use of different formu-
lations of NPs, variation of the incubation time, type of 
cells, and modifying the energy conditions of the cell cul-
ture. The latter condition was evaluated because endocy-
tosis is an active cellular process, which requires energy 
(ATP).
The time required for the incorporation of NPs in a cell 
system is critical to evaluate its use for in  vivo applica-
tions. While NPs interacts with the plasma membrane, 
cell will package this “foreign agent” with different sur-
face molecules, allowing their uptake [42]. Generally, by 
increasing the time which cells are exposed to NPs, their 
uptake increases. However, this process will be finally 
determined by the balance between entry and excre-
tion of NPs. Time dependence in NPs incorporation 
was evaluated in PMBC, HeLa and SKOV-3. As shown 
in Fig.  2, HeLa (a) and SKOV-3 (b) show time-depend-
ence, as evidenced by a high mean fluorescence intensity 
(MFI) given by the encapsulated fluorophore, showing 
a similar behavior obtained by Liu et al. [25]. Neverthe-
less, the same phenomenon was not observed in PBMC. 
After 5  min of incubation, a high fluorescence intensity 
was observed, which did not vary under longer incuba-
tion, reaching stable values. Most cellular models used so 
far to investigate nanoparticle cellular uptake do not take 
into account cellular heterogeneity in the blood stream, 
for instance, the presence of macrophages or neutro-
phils. Differences in NPs uptake and/or NPs phagocy-
tosis can be found even between macrophages mouse 
strains dependent on their preference for either Th1- or 
Th2-responses [43]. The mentioned phenomena may 
explain why in our experiments performed with PBMC, 
we observed a faster NPs internalization compared to the 
other cell lines (Fig. 2c, d).
NPs concentration is another important feature to be 
analyzed because it can impact uptake efficiency and 
cytotoxicity induction. Thus, we evaluated concentration 
dependence in the uptake of PHBV nanoparticles. HeLa, 
SKOV-3 and PBMC cells were incubated for 2 h at 37 °C, 
5% CO2 with a solution of PHBV-RN at different con-
centrations: 1, 10, 100, 500 and 1000 µg/mL. Figure 3a–d 
shows that in all the three cell types, concentration-
dependence is observed, with an apparent saturation at 
500  µg/mL. Experiments performed in PBMC indicate 
that cells need a specific concentration to internalize 
NPs, although they can internalize less content compared 
to the other cell lines.
PBMC showed faster cellular uptake in time (compar-
ing with the other cells at 5 min). This phenomenon was 
not observed in the other cell lines probably because 
PBMC contains macrophages and neutrophils which 
endocytosis mechanism is most via phagocytosis [43]. 
Nevertheless, uptake after 5 min seems to be inefficient 
probably because PBMC are smaller cells compared to 
the other cell lines (HeLa and SKOV-3 cells are relative 
equal in size). This idea is supported by Fig.  2d, which 
shows that PBMC uptake with different concentrations 
reach a plateau, absorbing less NPS than the other cell 
lines. On the other hand, cell lines (which are derived 
from a tumor) display a high metabolic rate, process that 
can respond to a higher cellular uptake without reaching 
a plateau. This effect was more evident in HeLa cells than 
SKOV-3 cells.
We have estimated an approximate number of NPs at a 
given NP mass concentration depicted in Fig. 3, following 
the previous data from Vilos et  al. [32]. In this way, the 
fluctuation in the number of NPs at 500 µg/mL compared 
to 1000 µg/mL represents only a twofold increase in pico-
moles/mL. It must be noted that an increase in the con-
centration of the solution might not be “saturating” the 
cells, because the NPs could enter progressively. Proba-
bly, at a high solution concentration such as 1000 µg/mL, 
NPs can enter in similar extent than at 500 µg/mL to the 
cells, as Fig. 3 shows, but probably afterwards, every NP 
can eventually enter the cells.
Internalization and processing of nanoparticles into 
the cells is an active process, which requires energy to 
be performed [44]. Dependence of energy (i.e. ATP) was 
assessed in HeLa and SKOV-3 cells. Both cell lines were 
incubated at 4  °C, after that the uptake of nanoparticles 
was quantified. As seen in Fig.  4, when both cell lines 
were incubated at 4 °C a decrease of NPs internalization 
was observed, suggesting endocytosis inhibition. Other 
groups also have reported this behavior. Qaddoumi et al. 
[20] reported a decrease of about 90% in the uptake of 
PLGA nanoparticles in rabbit conjunctival epithelial cells 
(RCEC), while Liu et al. [25] also observed a decrease in 
Fig. 1 PHBV nanoparticle micrograph. Representative image of PHBV 
nanoparticles (naked) by transmission electron microscopy (TEM). 
Objective ×49.000 magnification. Bar size 35 nm
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Fig. 2 Quantification of the cellular uptake of PHBV nanoparticles: time dependency. To evaluate time dependency in the cellular uptake of NPs, 
HeLa (a), SKOV‑3 (b) and PBMC (c) cells were incubated with a 100 µg/mL PHBV‑RN at several times. d Mean fluorescence intensity analysis of the 
three different cells. Mean fluorescence intensity was determined by flow cytometry (n = 3)
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Fig. 3 Quantification of the cellular uptake of PHBV nanoparticles. Concentration dependency. To evaluate concentration dependency in the 
cellular uptake of NPs, HeLa (a), SKOV‑3 (b) and PBMC (c) were incubated with a PHBV‑RN solution at different concentrations (1, 10, 100, 500 and 
1000 µg/mL) for 2 h. d Mean fluorescence intensity analysis of the three different cells. Mean fluorescence intensity was determined through flow 
cytometry (n = 3)
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uptake of polymeric nanoparticles in human cell lines 
Hep-G2, HuH-7, and PLC. By the other hand, treatment 
with sodium azide (SA) solution, which blocks electron 
transport chain, showed a decrease of the entry of NPs, 
however, this decay is less significant than the observed 
at 4  °C. One possible explanation for this phenomenon 
is that SA inhibits synthesis of ATP, then cells may use 
exogenous ATP for operation, allowing entry of PHBV 
nanoparticles, as been suggested by Gratton et  al. [39]. 
Other researchers have evaluated inhibition of endocy-
tosis adding sodium azide, obtaining similar results [45]. 
All these results suggest that uptake of PHBV nanopar-
ticles is a time, concentration, and energy-dependent 
process.
To study the effect of NPs on cell viability, we analyzed 
cell viability with annexin V by flow cytometry and cas-
pase-3 by immunofluorescence. Results show no signifi-
cant levels of cytotoxicity induced by the NPs in HeLa 
and SKOV-3, which was demonstrated using different 
assays and different concentrations and incubation times 
(Additional file 3: Figure S3).
Endocytosis mechanism of PHBV nanoparticles
To determine endocytosis mechanism of PHBV nano-
particles, we used fluorescent marker WGA, which selec-
tively recognizes plasma membrane structures. HeLa 
and SKOV-3 cell lines were incubated for 5  min with a 
PHBV-FITC solution and subsequently fixed for analysis. 
In Fig. 5 is observed colocalization of nanoparticles with 
WGA marker (arrowheads), demonstrating that uptake 
is performed by a plasma membrane coated compart-
ment in both cancer cell lines (HeLa 99.98% and SKOV-3 
99.95% of colocalization).
As a next step, we assessed whether entry of PHBV 
NPs is done through classical endocytosis ways. For 
this purpose, EEA-1 (early endosomes marker) (Fig.  6) 
and CAV-1 (caveolae-mediated endocytosis marker) 
(Fig. 7) were used. Both cell lines were exposed for 5 and 
15 min to PHBV-RN solution and then fixed. As shown 
in Fig. 6, HeLa cell line shows clear colocalization of NPs 
with early endosomes showing 99.42% of colocalization 
at 5  min and 99.39% of colocalization at 15  min, while 
SKOV-3 cells colocalization is strongly lesser showing 
21.17% of colocalization at 5  min and 23.08% of colo-
calization at 15 min. Furthermore, Fig. 7 shows in HeLa 
cells some colocalization of PHBV nanoparticles with 
endosomes coated with caveolae (41.46% of colocaliza-
tion at 5  min and 30.62% of colocalization at 15 min). 
While in SKOV-3 cells, colocalization with CAV-1 was 
not observed, evidencing that PHBV NPs do not enter the 
cells through caveolae-coated vesicles, although SKOV-3 
have been described as one of the few ovarian carcinoma 
cells expressing caveolin-1 protein [46]. Experiments 
conducted by Ekkapongpisi et al., showed that negative-
coated silica nanoparticles were uptaken by a caveolin-
independent mechanism by SKOV-3 cells, which was 
similar to neutral PHBV nanoparticles described with 
mesoporous silica and polystyrene nanoparticles [47].
In contrast to clathrin-mediated, classic route, caveolar 
uptake has been suggested to avoid lysosomes. Caveolae 
Fig. 4 Quantification of the cellular uptake of PHBV nanoparticles: energy dependency. To evaluate energy dependency in the cellular uptake of 
NPs, HeLa (a) and SKOV‑3 cells (b) were incubated with 100 µg/mL PHBV‑RN under different conditions (37, 4 °C, sodium azide). Mean fluorescence 
intensity was determined through flow cytometry (n = 3). One‑way ANOVA and Bonferroni statistical test were used (**p < 0.01, ***p < 0.001, 
****p < 0.0001)
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vesicles fuse with caveosomes, delivering their content to 
other cellular compartments. By avoiding acidic routes, a 
caveolar pathway may be advantageous for drug delivery. 
In this manner, ligands can be developed to target caveo-
lar domains and reaching a more efficient delivery [48].
Macropinocytosis mechanism was also indirectly eval-
uated. This pathway is characterized by the rearrange-
ment of actin filaments in the cytoplasm when a particle 
is incorporated. As a marker of actin monomers, Phalloi-
din, which is a mycotoxin that binds irreversibly to actin 
monomers, was conjugated to Alexa Fluor® 488 fluoro-
phore. HeLa and SKOV-3 cell lines were incubated for 
15 and 30 min with a PHBV-RN solution. Figure 8 shows 
that HeLa exhibits stress fibers in the presence of PHBV 
nanoparticles (arrowheads). These fibers are character-
istic of rearrangement of actin filaments in cellular pro-
cesses such as macropinocytosis. It is important to note 
that in SKOV-3, these types of fibers are not seen, show-
ing the same form as control treatment.
In summary, NPs showed different cell entry ways 
depending on the cell type; specifically, in SKOV-3, NPs 
appear to enter through an independent way from the 
traditional routes, unlike the behavior observed in HeLa 
cells (summary of the colocalization analysis is given in 
Table 2).
To determine the participation of the proteins from the 
cell membrane in the uptake of NPs, a reducible biotin 
assay was performed. By using a reducing agent such as 
glutathione, this method allows discriminating surface 
proteins that enter into the cell under a certain condi-
tion. As shown in Fig. 9, apparently there were no specific 
proteins involved in the incorporation of nanoparticles, 
because no differences were observed in the protein pat-
tern obtained with NPs compared to the control con-
dition without treatment. However, it is important to 
remark that the protein membrane pattern evaluated by 
western blot is completely different between both cell 
lines, suggesting that endocytosis machinery and plasma 
membrane proteins together with its dynamics may be 
different among them. This observation could explain 
our immunofluorescence results that showed that actin 
filaments, which are the major cytoskeletal proteins, are 
not acting in the NPs entry to SKOV-3 cells, differently to 
Hela cells.
Furthermore, to determine the final fate of the NPs 
in both cell lines, colocalization with LAMP-1 (Lyso-
some-Associated Membrane Protein 1) antibody was 
performed by immunofluorescence (Figs. 10, 11), show-
ing that in both cases NPs do colocalize with lysosomes 
but at different times: in HeLa cells, transit towards lys-
osomes was faster than in SKOV-3, probably due to that 
in Hela, the classical entry pathway is preferred by the 
NPs, allowing more expedite transit to the lysosomes, 
unlike SKOV-3. Moreover, in experiments performed 
with HL-60, a human promyelocytic leukemia cell line, 
after 4  h of incubation with NPs containing the fluoro-
phore FITC, its content was observed in the cytoplasm 
meaning that somehow NP content may be released by 
Fig. 5 Characterization of the endocytosis mechanism using WGA marker. HeLa and SKOV‑3 cells were incubated with PHBV‑FITC for 5 min at 37 °C, 
in the presence of Alexa Fluor® 555‑conjugated WGA. Later, cells were fixed and observed by fluorescence microscopy. Hoechst 33342 was used as 
a nuclear stain. Objective: ×60 magnification. Bar size 10 µm
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Fig. 6 Characterization of the endocytosis mechanism using EEA‑1 marker. HeLa (a–c) and SKOV‑3 (d–f) cells were incubated with PHBV‑RN nano‑
particles for 15 min at 37 °C; then cells were fixed and permeabilized. Later, an immunofluorescence was performed using anti‑EEA1 (1:100) and 
anti‑mouse Alexa Fluor® 488 (1:500) as primary and secondary antibody respectively. Finally, cells were observed through fluorescence microscopy. 
Hoechst 33342 was used as nuclear stain. Objective: ×60 magnification. Bar size 10 µm
Fig. 7 Characterization of the endocytosis mechanism using CAV‑1 marker. HeLa (a–c) and SKOV‑3 (d–f) cells were incubated with PHBV‑RN nano‑
particles for 15 min at 37 °C, then cells were fixed and permeabilized. Later, an immunofluorescence was performed using anti‑CAV1 (1:100) and 
anti‑mouse Alexa Fluor® 488 (1:500) as primary and secondary antibody respectively. Finally, cells were observed through fluorescence microscopy. 
Hoechst 33342 was used as nuclear stain. Objective: ×60 magnification. Bar size 10 µm
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the lysosomes where NPs may be degraded (data not 
shown).
To evaluate NPs final fate through a different approach, 
we performed an experiment with NPs encapsulating 
LysoTracker® probe, which consist on a fluorophore 
linked to a weak base that is only partially protonated at 
neutral pH [49]. This probe is highly selective for acidic 
organelles. If the NPs release their content in the lyso-
some, it may be detected by fluorescence microscopy. In 
this way, fluorescence is not detected when LysoTracker® 
is trafficking through the endosomes. Our results in 
Fig. 12 shows that after 4 h, fluorescence can be detected, 
demonstrating that NPs are degraded in the lysosome, 
releasing their content. In  vitro degradation of PHBV 
has been shown very slow [50]. At extreme conditions, 
such as at acid/basic pH, degradation seems to undergo 
by a decrease in the molecular weight and then, by a 
weight loss, when the mechanical strength is lost, and the 
remaining PHBV breaks down into small fragments [51].
Fig. 8 Evaluation of actin filaments rearrangement in the presence of PHBV nanoparticles. HeLa (a–d) and SKOV‑3 (e–h) cells were incubated with 
PHBV‑RN for 15 and 30 min at 37 °C; then cells were permeabilized and incubated with Phalloidin Alexa Fluor® 488 conjugated. Hoechst 33242 was 
used as nuclear stain. Objective: ×60 magnification. Bar size 10 µm
Table 2 Extent of  colocalization of  PHBV nanoparticles 
with endocytosis markers in HeLa and SKOV-3 cells
CAV-1 EEA-1 WGA
5 min 15 min 5 min 15 min 5 min
HeLa (%) 41.46 30.62 99.42 99.39 99.98
SKOV‑3 (%) 0 0 21.17 23.08 99.95
Fig. 9 Analysis of proteins involved in cellular uptake of PHBV nanopar‑
ticles. HeLa and SKOV‑3 cells were subjected to reducible biotin assay 
to determine possible membrane proteins involved in nanoparticles 
uptake. 40 µg of proteins from cell lysate were resolved through SDS‑
PAGE, then transferred to PDVF membrane and finally, incubated with 
streptavidin‑HRP (1:1000). β‑actin (47 kDa) was used as loading control
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Fig. 10 Determination of final nanoparticle fate in HeLa cells. HeLa cells were incubated with PHBV‑RN nanoparticles for 15 min (a–c) and 1 h (d–f) 
at 37 °C; then cells were fixed and permeabilized. Later, an immunofluorescence was performed using anti‑LAMP1 (1:100) and anti‑mouse Alexa 
Fluor® 488 (1:500) as primary and secondary antibody respectively. Finally, cells were observed through fluorescence microscopy. Hoechst 33342 
was used as nuclear stain. Objective: ×60 magnification. Bar size 10 µm
Fig. 11 Determination of final nanoparticle fate in SKOV‑3 cells. SKOV‑3 cells were incubated with PHBV‑RN nanoparticles for 15 min (a–c) and 1 h 
(d–f) at 37 °C, then cells were fixed and permeabilized. Later, an immunofluorescence was performed using anti‑LAMP1 (1:100) and anti‑mouse 
Alexa Fluor® 488 (1:500) as primary and secondary antibody respectively. Finally, cells were observed through fluorescence microscopy. Hoechst 
33342 was used as nuclear stain. Objective: ×60 magnification. Bar size 10 µm
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Fig. 12 Evaluation of nanoparticle degradation. HeLa and SKOV‑3 cells were incubated with PHBV‑Lysotracker® DND‑99/nanoparticles for 4 h at 
37 °C, then cells were fixed and observed through fluorescence microscopy. Objective: ×60 magnification. Bar size 10 µm
Fig. 13 PHBV nanoparticle intracellular trafficking pathway in HeLa and SKOV‑3 cells scheme. Our results showed different endocytosis pathway 
depending on the cell context but the same final destination
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When cells were incubated with PHBV NPs, after 
trafficking through the endo-lysosome pathway, which 
finally ends at lysosomes, these organelles enter into a 
special stage where they fused and get polarized, resem-
bling what normally happens during autophagy and 
immunological synapsis [52, 53]. To investigate whether 
NPs/cell incubation may trigger autophagy, we analyze 
LC3 expression by western blot in the two different cell 
lines, which showed no LC3 expression (data not shown) 
suggesting that lysosomal fusion not be triggering by an 
autophagy event [54]. These findings lead to propose the 
recruitment of a possible MTOC (Microtubule Organiz-
ing Center) towards a particular area, allowing the local 
regulation of potential exocytosis and endocytosis pro-
cesses by concentrating at a specific place the required 
molecular machinery. A scheme of PHBV NPs entry 
pathway for HeLa and SKOV-3 cell lines suggested in this 
article is depicted in Fig. 13.
Conclusion
We investigated the cellular uptake mechanism of PHBV 
for intracellular delivery into HeLa and SKOV3 cells. Our 
experimental results showed that this process is time, 
concentration and energy-dependent, and the inter-
nalization mechanism depends on the cell line. Results 
described above, give us a general understanding of the 
cellular processes required for nanoparticle internaliza-
tion, which contributes to understanding further targeting 
properties of PHBV enhancing their targeting efficiency.
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